NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AUPH

$16.08

−$0.04 (−0.25%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AUPH with… →

AUPH Key Statistics

As of Sep 4, 2026
Trading
Open
$15.97
Previous Close
$16.12
Day's Range
15.93–16.22
52-Week Range
10.34–19.25
Volume
526.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$2.14B
P/E Ratio
7.05
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.07
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.87
EPS (ttm)Profit attributable to each share over the last twelve months.
2.28
Financials (FY)
Revenue (FY)
$283.06M+20.38%
Net Income (FY)
$287.20M+4893.08%
Profit marginThe share of revenue left as profit after all costs and taxes.
100.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
133.05M
1-Year Return
+28.33%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AUPH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.82%
2025+77.62%
2024−0.11%
2023+108.10%
2022−81.11%
2021+65.37%
2020−31.74%
2019+197.07%
2018+50.55%
2017+115.71%
2016 (partial year)−42.78%

As of September 4, 2026.

AUPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$283.06M$287.20M101.5%
2024$235.13M$5.75M2.4%
2023$175.51M−$78.02M−44.5%
2022$134.03M−$108.18M−80.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$283.06M$250.39M$106.56M$287.20M101.5%
2024$235.13M$206.89M$18.42M$5.75M2.4%
2023$175.51M$161.37M−$91.69M−$78.02M−44.5%
2022$134.03M$128.37M−$111.47M−$108.18M−80.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AUPH Valuation vs Biotechnology Median

Median of 656 stocks
MetricAUPHBiotechnology medianvs median
P/E7.0512.5744% below
P/S ratio6.8715.2655% below
Profit margin100.84%0.00%100.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aurinia Pharmaceuticals Inc. (AUPH) is capitalised at $2.14B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 128.

AUPH last closed at $16.08 on September 4, 2026. That is −$0.04 (−0.25%) against the previous close. Over the past 52 weeks the price has ranged from $10.34 to $19.25. The latest close sits 55.51% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $283.06M. Against the prior fiscal year total of $235.13M, that is a change of +20.38%. Net income for the same year was $287.20M. That is +4,893.08% against the prior fiscal year. Profit margin runs at 100.84%. That is 100.8 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 2.28.

Across the 4 fiscal years on file, revenue moves from $134.03M in 2022 to $283.06M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 7.05 times earnings. That is 43.91% below the Biotechnology median of 12.57. On forward earnings the ratio is 15.07. The price-to-sales ratio is 6.87. On price-to-sales that is 55% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.41. Daily returns over the trailing 10 years annualize to a volatility of 70.67%. The trailing one-year price return is +28.33%. Across 10 years the annualized return works out at +22.87%.

Growth & Income

No dividend is on file for AUPH.

The strongest complete calendar year on file is 2019 at +197.07%; the weakest is 2022 at −81.11%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the price is +0.82% year to date.

Peer Comparison

Aurinia Pharmaceuticals Inc. (AUPH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aurinia Pharmaceuticals Inc. AUPH $2.14B 7.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Aurinia Pharmaceuticals Inc. trades at a P/E of 7.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Visit website →